scholarly article | Q13442814 |
P6179 | Dimensions Publication ID | 1032386471 |
P356 | DOI | 10.1007/S10620-005-9071-3 |
P698 | PubMed publication ID | 16773434 |
P2093 | author name string | Charles J Lightdale | |
Clara Hwang | |||
Bernard Hamelin | |||
Colleen Schmitt | |||
P2860 | cites work | Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification | Q24670182 |
Esomeprazole provides improved acid control vs. omeprazole In patients with symptoms of gastro-oesophageal reflux disease | Q31404948 | ||
Meta-analysis of randomized controlled trials comparing standard clinical doses of omeprazole and lansoprazole in erosive oesophagitis | Q31811132 | ||
Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole | Q34320782 | ||
Relation between oesophageal acid exposure and healing of oesophagitis with omeprazole in patients with severe reflux oesophagitis | Q34409644 | ||
Epidemiology and natural history of gastro-oesophageal reflux disease | Q35378865 | ||
Double-blind comparison [correction of Double-blind, placebo-controlled comparison] of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease. The European Rabeprazole Study Group | Q39442247 | ||
Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis | Q39455544 | ||
Pantoprazole and omeprazole in the treatment of reflux oesophagitis: a European multicentre study. | Q39469901 | ||
Critical issues in the management of gastroesophageal reflux disease. | Q39474663 | ||
Two doses of omeprazole versus placebo in symptomatic erosive esophagitis: The U.S. multicenter study | Q39504404 | ||
The pathogenesis of gastroesophageal reflux disease: the relationship between epithelial defense, dysmotility, and acid exposure | Q41451958 | ||
The endoscopic assessment of esophagitis: a progress report on observer agreement. | Q52888202 | ||
An evidence-based appraisal of reflux disease management--the Genval Workshop Report | Q61537811 | ||
Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial | Q61826600 | ||
Appropriate acid suppression for the management of gastro-oesophageal reflux disease | Q67555208 | ||
The Second Canadian Gastroesophageal Reflux Disease Consensus: moving forward to new concepts | Q77929702 | ||
P433 | issue | 5 | |
P921 | main subject | esophagitis | Q298230 |
omeprazole | Q422210 | ||
esomeprazole | Q553223 | ||
multicenter clinical trial | Q6934595 | ||
P304 | page(s) | 852-857 | |
P577 | publication date | 2006-05-01 | |
P1433 | published in | Digestive Diseases and Sciences | Q15716711 |
P1476 | title | A multicenter, randomized, double-blind, 8-week comparative trial of low-dose esomeprazole (20 mg) and standard-dose omeprazole (20 mg) in patients with erosive esophagitis | |
P478 | volume | 51 |
Q42283418 | Comparative effectiveness and acceptability of the FDA-licensed proton pump inhibitors for erosive esophagitis: A PRISMA-compliant network meta-analysis |
Q40316973 | Comparative efficacy of esomeprazole and omeprazole: Racemate to single enantiomer switch. |
Q35987201 | Efficacy of esomeprazole in treating acid-related diseases in Japanese populations |
Q37032564 | Esomeprazole: a review of its use in the management of gastric acid-related diseases in adults |
Q48458474 | Functional heartburn, nonerosive reflux disease, and reflux esophagitis are all distinct conditions--a debate: con. |
Q33446555 | GORD in adults |
Q24289016 | Gastroesophageal Reflux Disease Relief in Patients Treated with Rabeprazole 20 mg versus Omeprazole 20 mg: A Meta-Analysis |
Q37260543 | Managing peptic ulcer and gastroesophageal reflux disease in elderly Chinese patients--focus on esomeprazole |
Q43854731 | Occurrence of community-acquired respiratory tract infection in patients receiving esomeprazole: retrospective analysis of adverse events in 31 clinical trials |
Search more.